Rankings
▼
Calendar
KNSA Q3 2025 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$181M
+61.2% YoY
Gross Profit
$97M
53.8% margin
Operating Income
$24M
13.3% margin
Net Income
$18M
10.2% margin
EPS (Diluted)
$0.23
QoQ Revenue Growth
+15.3%
Cash Flow
Operating Cash Flow
$34M
Free Cash Flow
$33M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$712M
Total Liabilities
$177M
Stockholders' Equity
$535M
Cash & Equivalents
$175M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$181M
$112M
+61.2%
Gross Profit
$97M
$63M
+54.9%
Operating Income
$24M
-$10M
+348.7%
Net Income
$18M
-$13M
+245.2%
Revenue Segments
Product
$181M
100%
← FY 2025
All Quarters
Q4 2025 →